Thomas Jefferson University

Jefferson Digital Commons
Wills Eye Hospital Papers

Wills Eye Hospital

2-26-2018

Submillimeter retinoblastoma monitoring following transpupillary
thermotherapy using hand-held optical coherence tomography
Mark McGarrey
Thomas Jefferson University

Thamolwan Surakiatchanukul
Thomas Jefferson University

Carol L. Shields
Thomas Jefferson University

Follow this and additional works at: https://jdc.jefferson.edu/willsfp
Part of the Ophthalmology Commons

Let us know how access to this document benefits you
Recommended Citation
McGarrey, Mark; Surakiatchanukul, Thamolwan; and Shields, Carol L., "Submillimeter
retinoblastoma monitoring following transpupillary thermotherapy using hand-held optical
coherence tomography" (2018). Wills Eye Hospital Papers. Paper 84.
https://jdc.jefferson.edu/willsfp/84
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital
Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is
a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections
from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested
readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been
accepted for inclusion in Wills Eye Hospital Papers by an authorized administrator of the Jefferson Digital
Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu.

International Journal
of Retina and Vitreous

McGarrey et al. Int J Retin Vitr (2018) 4:9
https://doi.org/10.1186/s40942-018-0112-4

Open Access

CASE REPORT

Submillimeter retinoblastoma
monitoring following transpupillary
thermotherapy using hand‑held optical
coherence tomography
Mark McGarrey, Thamolwan Surakiatchanukul and Carol L. Shields*

Abstract
Background: Precise, submillimeter visualization of retinal microstructures is useful for treatment monitoring of
retinoblastoma. Herein, we report the use of hand-held optical coherence tomography (HH-OCT) to document a
nearly-invisible retinoblastoma and monitor tumor response to transpupillary thermotherapy (TTT).
Case presentation: A 3-week-old boy was diagnosed with unilateral familial retinoblastoma in the left eye, classified as group B, and treated with intravenous chemoreduction. At 13-month follow-up, the tumor in the left eye
was regressed, and evaluation of the right eye revealed a microscopic, nearly invisible tumor measuring 372 µm in
thickness and 1.51 mm in basal dimension. The tumor was confirmed on HH-OCT and the diagnosis was changed
to bilateral familial retinoblastoma. The new tumor was subsequently treated with TTT and after 1 month, the tumor
regressed to an optically dense scar 166 µm in thickness by HH-OCT. Five months after TTT, the scar was clinically flat
and measured 73 µm.
Conclusions: HH-OCT has assumed a significant role in the monitoring of retinoblastoma in children. In this case,
imaging with HH-OCT allowed precise localization of the tumor and submillimeter monitoring of treatment response
following TTT.
Keywords: Eye, Retina, Retinoblastoma, Chemoreduction, Regression, Transpupillary thermotherapy, Optical
coherence tomography
Background
Optical coherence tomography (OCT) is an imaging technology that utilizes the predictable properties
of light refraction to produce precise cross sectional
images of the human fundus [1]. Following the popularization of OCT since 1991, OCT technologies including spectral domain OCT (SD-OCT) have allowed
for non-invasive, higher-resolution evaluation of retinal and choroidal microstructures. Subsequent technological advancements have given rise to hand-held
OCT (HH-OCT), a portable SD-OCT unit, that can be

used intra-operatively to image the eyes of children and
non-cooperative patients [2]. HH-OCT has proven particularly useful in detection and monitoring of small or
“invisible” parafoveal retinoblastomas as well as estimating visual acuity potential in preverbal children [3–5].
Herein, we report a 3-week-old boy with familial retinoblastoma who was detected to have a minimally
elevated submillimeter tumor, confirmed on HH-OCT.
Following treatment, documentation of tumor regression by HH-OCT was important in confirming complete
tumor response.
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Case presentation
A 3-week-old white male, with a family history of maternal retinoblastoma, presented for clinical evaluation after
fetal ultrasound revealed a tumor in the left eye (OS). On
examination, visual acuity was fix and follow in each eye
and leukocoria OS was noted. Funduscopic evaluation
right eye (OD) showed no tumor, whereas fundus evaluation OS (Fig. 1a) revealed a macular retinoblastoma
measuring 10.0 mm in basal dimension and 5.0 mm in
thickness, classified as group B familial retinoblastoma.
The patient received six cycles of intravenous chemoreduction (CRD) using vincristine, etoposide, and carboplatin. Following CRD, the right eye remained normal and
the left eye (Fig. 1b) showed type III regression, with partial calcification and regressed tumor measuring 6.0 mm
in basal dimension and 2.1 mm in thickness.
At a 13-month follow-up, a new, minimally elevated
parafoveal retinoblastoma measuring 1.51 mm in diameter located 6.0 mm temporal to the foveola OD (Fig. 2a)
was detected by indirect ophthalmoscopy. The left eye
remained stable with a partially calcified scar. By HHOCT, the foveola OD was intact and the tiny parafoveal
retinoblastoma measured 372 µm in thickness and was
without subretinal fluid (Fig. 2b). Ultrasonography confirmed the tiny retinoblastoma OD of 1.5 mm thickness
and the regressed calcified retinal scar OS of 2.1 mm
thickness.
The diagnosis was changed to bilateral familial retinoblastoma, and the newly-diagnosed retinoblastoma OD
was treated with transpupillary thermotherapy (TTT)
using 300 mW power for 4 min with grey-white uptake.
One month later, retinoblastoma regression was noted
(Fig. 2c) and HH-OCT (Fig. 2d) revealed thickness
reduction to 166 µm. Five months after TTT, the scar was
clinically flat (Fig. 2e), measuring 73 µm on HH-OCT
(Fig. 2f ). There were no further tumors.
Discussion
Imaging technologies play a significant role in the detection, diagnosis, and selection of therapeutic options for
retinoblastoma. Previously, cross-sectional imaging of
retinoblastoma was only possible with ultrasonography,
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Fig. 1 Retinoblastoma regression in the left eye after 6 cycles of
intravenous chemoreduction. The left eye demonstrated a macular
retinoblastoma (a) measuring 10.0 mm in largest basal dimension
and 5.0 mm in thickness. After 6 cycles of chemoreduction, the tumor
(b) showed regression to 6.0 mm in basal dimension and 2.1 mm in
thickness

computed tomography, or magnetic resonance imaging.
These techniques were only able to detect medium to
large retinoblastoma and provide information on tumor
configuration, location, size, and extrascleral extension. However, high resolution HH-OCT has recently
become available for detection of small retinoblastomas
as depicted in Table 1 [3–8], and recently even those that
are sub-millimeter or nearly clinically invisible, as in this
case.
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Fig. 2 Retinoblastoma regression documented on hand-held optical coherence tomography (HH-OCT) in the right eye. The initially unaffected
right eye (a) demonstrated a small retinoblastoma temporal to the fovea of 1.51 mm in basal dimension and 372 µm in thickness (b). One month
following transpupillary thermotherapy (TTT), the tumor (c) showed regression, confirmed as a (d) hyperreflective scar on OCT of 166 µm thickness.
At 5 months after TTT, the flat scar (e) measured 73 µm thickness on HH-OCT (f)

HH-OCT is a portable SD-OCT unit, particularly
useful for imaging young children and uncooperative
patients. In 2004, Shields et al. [9] reported that time
domain OCT was more sensitive than clinical examination in detection and monitoring of a variety of macular
pathology in children such as cystoid macular edema and

subretinal fluid. Further studies have revealed that HHOCT is important for monitoring tumor regression [10],
detecting subclinical recurrence [6], identifying invisible
retinoblastoma [4, 5], and elucidating foveal microanatomy in children following retinoblastoma treatment [11].
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Table 1 Comparison of published cases of small retinoblastomas documenting tumor detection, regression, or recurrence by optical coherence tomography
Authors

Cao et al. [3]

Patient demographics

OCT findings
Tumor diameter (mm)

Tumor thickness (µm)

Distance
from foveola
(mm)

Distance
from optic
nerve (mm)

Descriptions

Machine

33-month-old
male

8.0 (6.5)a

4000 (2200)a

0.0 (0.2)a

Unspecified
(0.0)a

Exophytic mass
draped by
normal retina

iVue Optovue
with iStand

9-month-old
female

12.0 (8.0)a

6300 (3000)a

0.0 (0.5)a

Unspecified
(3.5)a

Exophytic mass
draped by
normal retina

7-month-old
male

11.0 (6.0)a

4000 (2600)a

0.0 (0.0)a

Unspecified
(2.5)a

Exophytic mass
draped by
normal retina

Unspecified

Unspecified

Unspecified

Unspecified

Ovoid; Outer
nuclear layer

Saktanasate et al. 2-month-old
[4]
male

iVue Optovue

Berry et al. [5]

7-week-old male Unspecified (3
tumors)

Unspecified

Unspecified

Unspecified

Dome-shaped;
InVivoVue, BiopOuter nuclear,
tigen
outer plexiform, and inner
nuclear layers

Park et al. [6]

3-week-old
female

639

1.85

Unspecified

Dome-shaped;
Outer nuclear
layerb

iVue Optovue

Soliman et al. [7]

Unspecified

Unspecified

Unspecified

Unspecified

Ovoidb; Inner
nuclear layer

Bioptigen Envisu
C2200/C2300

Unspecified

Dome-shapedb;
Outer retinal
layerb

iVue Optovue

2.10

Unspecified

Yarovaya et al. [8] 3-week-old
female

2.75

792

0.62

Current report

1.51

372

6.0

3-week-old male

9.0 Dome-shaped;
Inner retinal
layer

iVue Optovue

Reports from peer-reviewed journals in 2014-17 were included
a

Dimensions were re-measured after therapy

b

Per our interpretation of the published images

Conclusions
Imaging with HH-OCT was helpful in this case as it confirmed tumor presence and allowed for precise, submillimeter monitoring of tumor thickness and regression,
with preservation of foveal microanatomy. We encourage
all clinicians who manage retinoblastoma to consider the
use of HH-OCT for best monitoring of even the tiniest
tumors.
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